Global Cancer Generics Market to Register Double-Digit Growth through 2022, States RNCOS in Its New Research Report Now Available at MarketPublishers.
19 Oct 2016 • by Natalie Aster
LONDON – Today, the oncology market is rising at a swift pace, driven by the increasing cancer incidence worldwide and on-going advances of the pharmaceutical industry. As of 2015, the number of new cases of cancer registered across the globe exceeded 15.1 million. By 2025, this number is anticipated to outstrip 19.2 million.
Robust growth in the world’s cancer generics market is also propelled by the patent expiry of the major existing cancer drugs, or so called blockbuster cancer drugs.
From 2016 up till 2022, the worldwide cancer generics market is forecast to follow an upward trend, registering a double digit CAGR.
Injectables are recognised as the top and the most widely used type of cancer generic drugs. Breast cancer sector accounts for the largest share of the cancer generics market due to great number of generic drugs and increasing incidence of breast cancer worldwide. North America is the dominant regional market for cancer generics.
New RNCOS research report “Global Cancer Generics Market Forecast to 2022” presents a comprehensive overview of the world’s cancer generics market and discloses important historical and present info on the market performance. The publication delves deep into the market dynamics, reviews top drivers and challenges, covers the latest trends and developments having impact on the market growth. Moreover, the report profiles ten prominent market participants, disclosing reliable financial information and describing their product portfolios. The report discusses the key market strategies, pinpoints future possible opportunities and promising growth areas in the global cancer generics market, and also contains future projections up till 2022.
For other new insightful research report by RNCOS, kindly, follow to its page.